Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease
<p id="p0015">No treatment-related mortality or graft-versus-host disease occurred after alemtuzumab/total body irradiation conditioning in sickle cell disease adults.p>
•
<p id="p0020">Health-related quality of life improves in adult sickle cell disease patients after chemotherapy-free hematopoietic stem cell transplantation.p>